Wannan cibiyar guda ɗaya, bazuwar, makafi biyu, tsarin kula da wuribo I na nazarin asibiti yana shirin yin rajistar batutuwa 56 don kimanta juriya, aminci da halayen magunguna bayan gudanarwa ɗaya / da yawa a cikin masu sa kai na kasar Sin lafiya. Farfesa Wang Yongjun, shugaban Asibitin Tiantan na Beijing, Jami'ar Kiwon Lafiya ta Capital shine babban mai bincike. An ƙaddamar da binciken a hukumance a ranar 2 ga Disamba, 2021, tare da kashi na farko na batutuwa 4 a rukunin farko na allurai a ranar 8 ga Disamba.
"Farkon yin allurai a cikin binciken farko na asibiti na Simcere na SIM0307 wani muhimmin mataki ne na ci gaba a ci gaban duniya na AER-271 yayin da muke neman kafa wata bukata, magani mai ma'ana don cutar bugun jini," in ji Mike Gresser, Babban Jami'in Kimiyya na Aeromics. . Gresser ya kara da cewa, "tPA da sauran magungunan thrombolytic suna haifar da reperfusion, wanda ya zama dole, amma sau da yawa yakan haifar da raunin da ya faru. Jiyya tare da AER-271 tare da maganin thrombolytic ana tsammanin zai taimaka rage edema ta hanyar tsoma baki da wuri a cikin tsarin kumburi wanda ya haifar da sakewa ta hanyar tPA, thrombectomy na hannu da sauran jiyya na thrombolytic.
Aeromics da Simcere sun shiga cikin haɗin gwiwa da yarjejeniyar lasisi na musamman a cikin Nuwamba 2019 don AER-271, wani mataki na rigakafin edema da ake haɓaka don magance bugun jini da sauran alamomi a cikin Babban China (China China, Hong Kong, Macau da Taiwan). Bisa yarjejeniyar, Simcere ne zai dauki nauyin ci gaban asibiti da kasuwanci na AER-271 a babbar kasar Sin. A watan Afrilun 2021, Hukumar Kula da Kayayyakin Likitoci ta kasar Sin (NMPA) ta amince da gwajin asibiti na SIM0307 don nuna alamun edema na kwakwalwa bayan mummunan bugun jini na ischemic.
"Mun yi matukar farin ciki da ganin SIM0307 ya kai wani muhimmin ci gaba a kasar Sin." Dokta Renhong Tang, Babban Darakta da Mataimakin Shugaban Kamfanin Simcere, ya ce, "Ci gaban ci gaban wannan kwayar halitta yana nuna haɗin gwiwar fasaha na Aeromics da Simcere R & D, ci gaban asibiti, masana'antu, da kasuwanci."
"Muna ci gaba da yaba dangantakarmu da Simcere yayin da ƙungiyoyinmu ke aiki tare don ciyar da wannan shirin gaba. Duk abin da muka yi imani game da binciken su, haɓakawa da ƙarfin masana'anta sun tabbatar da gaskiya, kuma yanayin haɗin gwiwar ƙungiyar su ya wuce tsammaninmu. Mun yi farin cikin ganin ci gaban Simcere yayin da muke shirye-shiryen gwajin namu na Mataki na IIa a nan Amurka." in ji Thomas Zindrick, Shugaban Hukumar Aeromics.
Shugaban Kamfanin Simcere & Shugaba, Mista Jinsheng Ren ya kammala, “Muna alfahari da haɓaka SIM0307 (AER-271), yayin da muke fassara ilmin halitta wanda ya lashe lambar yabo ta Nobel zuwa hanyoyin warkewa masu ma'ana ga marasa lafiya da ke da iyakacin zaɓuɓɓukan magani. Bugu da ƙari, SIM0307 yana da yuwuwar yin aiki tare da wasu samfuran a cikin fayil ɗin CNS na Simcere kamar Sanbexin® wanda zai iya ƙara haɓaka sakamakon bugun jini. Muna sa ran samun ci gaba mai ban sha'awa a nan gaba tare da haɗin gwiwa tare da ƙungiyar Aeromics. "
